While previously mentioned studies are contradictory about the prognostic value of TERT mutation determination, very recent meta-analyses have concluded that the TERT may be a valuable marker for individual prognostic value, as TERT mutation increases the risk of death and decreases the survival time of urothelial carcinoma patients [37]; in addition the presence of TERT-promoter mutations could even negatively affect the outcome of urothelial carcinoma patients treated with chemotherapy or immunotherapy [38]. This evidence concerns the gene TERT and urothelial carcinoma.